ArticleIrish journal of medical science2026
Diagnostic value of tumor volume for differentiating between parathyroid carcinoma and adenoma.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe distinction between parathyroid carcinoma (PC) and parathyroid adenoma (PA) remains a considerable clinical challenge. This study evaluated the discriminatory performance of pathology-derived tumor volume for differentiating PC from PA and compared it with tumor length and routine biochemical parameters.
methodsThis retrospective matched case-control study included 15 PC cases and 45 age- and sex-matched PA controls treated between 2008 and 2024. Tumor volume was calculated from three-dimensional pathological specimen measurements using the ellipsoid formula. Discriminatory performance was assessed by receiver operating characteristic (ROC) analysis, with areas under the curve (AUCs) compared using DeLong's test. Parsimonious multivariable logistic regression models assessed the independent association between tumor volume and PC.
resultsTumor volume showed the highest discriminatory performance (AUC = 0.985, 95% CI: 0.914-1.000), with an exploratory pathology-derived cut-off of > 4.71 cm³ yielding 100.0% sensitivity and 97.8% specificity. Its AUC was significantly higher than those of parathyroid hormone, alkaline phosphatase, calcium, and albumin (all P < 0.05), whereas the difference from tumor length was not statistically significant (AUC = 0.937; ΔAUC = 0.048; P = 0.055). Tumor volume remained independently associated with PC after separate adjustment for PTH, ALP, calcium, and albumin (adjusted OR range, 2.017-2.446; all P ≤ 0.003).
conclusionPathology-derived tumor volume demonstrated excellent discriminatory performance for differentiating PC from PA and outperformed the evaluated biochemical markers, although its advantage over tumor length was not statistically significant. As the identified cut-off is pathology specimen-derived, prospective validation using standardized preoperative radiological volumetry is required before its clinical utility can be established.
Indexed as
Identifiers
42771255What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.